NASDAQ: SRZN
Surrozen Inc Stock Forecast, Predictions & Price Target

Analyst price target for SRZN

Based on 1 analyst offering 12 month price targets for Surrozen Inc

Min Forecast
$45.00+297.53%
Avg Forecast
$45.00+297.53%
Max Forecast
$45.00+297.53%

Should I buy or sell SRZN stock?

Based on 1 analyst offering ratings for Surrozen Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SRZN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates SRZN as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their SRZN stock forecasts and price targets.

SRZN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-01-03

1 of 1

Forecast return on equity

Is SRZN forecast to generate an efficient return?

Company
-155.41%
Industry
10,837.71%
Market
237.47%
SRZN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SRZN forecast to generate an efficient return on assets?

Company
-18.35%
Industry
4,419.64%
SRZN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SRZN earnings per share forecast

What is SRZN's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$4.15
Avg 2 year Forecast
-$2.71

SRZN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SRZN$11.32$45.00+297.53%Strong Buy
BIVI$2.10N/AN/A
CMMB$1.98$11.00+455.56%Buy
ATHE$3.45$8.00+131.88%Strong Buy
LEXX$2.06$10.00+385.44%Buy

Surrozen Stock Forecast FAQ

Is Surrozen Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SRZN) stock is to Strong Buy SRZN stock.

Out of 1 analyst, 1 (100%) are recommending SRZN as a Strong Buy, 0 (0%) are recommending SRZN as a Buy, 0 (0%) are recommending SRZN as a Hold, 0 (0%) are recommending SRZN as a Sell, and 0 (0%) are recommending SRZN as a Strong Sell.

If you're new to stock investing, here's how to buy Surrozen stock.

What is SRZN's earnings growth forecast for 2025-2026?

(NASDAQ: SRZN) Surrozen's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 57.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 59.2%.

Surrozen's earnings in 2025 is -$44,438,000.On average, 1 Wall Street analyst forecast SRZN's earnings for 2025 to be -$13,486,662, with the lowest SRZN earnings forecast at -$13,486,662, and the highest SRZN earnings forecast at -$13,486,662.

In 2026, SRZN is forecast to generate -$8,806,953 in earnings, with the lowest earnings forecast at -$8,806,953 and the highest earnings forecast at -$8,806,953.

What is SRZN's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: SRZN) forecast ROE is -155.41%, which is considered weak.

What is SRZN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SRZN price target, the average SRZN price target is $45.00, with the highest SRZN stock price forecast at $45.00 and the lowest SRZN stock price forecast at $45.00.

The Wall Street analyst predicted that Surrozen's share price could reach $45.00 by Jan 3, 2026. The average Surrozen stock price prediction forecasts a potential upside of 297.53% from the current SRZN share price of $11.32.

What is SRZN's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: SRZN) Surrozen's current Earnings Per Share (EPS) is -$17.05. On average, analysts forecast that SRZN's EPS will be -$4.15 for 2025, with the lowest EPS forecast at -$4.15, and the highest EPS forecast at -$4.15. In 2026, SRZN's EPS is forecast to hit -$2.71 (min: -$2.71, max: -$2.71).

What is SRZN's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: SRZN) forecast ROA is -18.35%, which is lower than the forecast US Biotechnology industry average of 4,419.64%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.